COMPOSITION:
TRIBLEND D2
Each uncoated bilayer tablet contains-
Glimepiride………………………….. 1 mg
Metformin (Sustain Release)… 500 mg
Dapagliflozin ……………………….. 10 mg
GLIMEPIRIDE:
Glimepiride is an oral medication belongs to the sulfonylurea class, used to manage type 2 diabetes mellitus. It belongs to a class of drugs called sulfonylureas and works by stimulating the pancreas to release more insulin, which helps lower blood sugar levels.
DAPAGLIFLOZIN:
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increasing urinary glucose excretion.
METFORMIN:
Metformin is an antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce significant hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia.
INDICATIONS:
TRIBLEND D tablets, used once per day, are indicated as an adjunct to diet and exercise, to lower blood glucose. It is indicated as second-line therapy when diet, exercise, and single agents or dual therapy do not result in adequate glycaemic control in patients with type 2 diabetes.
DOSAGE:
As prescribed by a physician.
DISCLAIMER:
All content published online is for informational purposes only. It is not intended to be a substitute for professional medical advice. Always seek the guidance of your doctor with any questions you may have regarding your health, medical condition, or any medicines.